Chinese Association of Idaho State University (CAISU)
Peptide Raw Powder Synthesis CAS 910463-68-2 Semaglutide API
Peptide Raw Powder Synthesis CAS 910463-68-2 Semaglutide API
Semaglutide powder is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use
Semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
Semaglutide has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
Semaglutide is not a substitute for insulin. Semaglutide is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.
Semaglutide powder is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use
Semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
Semaglutide has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
Semaglutide is not a substitute for insulin. Semaglutide is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.
查看次数： 6
评论
您必须是爱达荷州立大学中国学生学者联谊会 的成员才能加评论！
加入 爱达荷州立大学中国学生学者联谊会